Swiss Sarcoma Network: Prediction Model for Patient Selection in Sarcoma Care

Sponsor

Kantonsspital Winterthur KSW (Other)

Overall Status

Recruiting

CT.gov ID

NCT04300257

Collaborator

SwissSarcomaNetwork (Other)

600

Enrollment

Locations

122.4

Anticipated Duration (Months)

Patients Per Site

0.6

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The primary significance of this project is to perform a detailed analysis to assess the diagnostics, treatment and follow-up care, to develop a prediction model for future patient selection regarding various diagnostic and treatment procedures.

Condition or Disease	Intervention/Treatment	Phase
Sarcoma

Detailed Description

Within the framework of interdisciplinary cooperation for a sarcoma problem, predictive and prognostic criteria will be developed that improve the treatment and particularly outcome.

The outcome variables include patient characteristics, tumor types and characteristics, histology, management and treatment strategies as well as recurrence rate and overall survival.

Study Design

Study Type:

Observational [Patient Registry]

Anticipated Enrollment :

600 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

Swiss Sarcoma Network: Prediction Model for Patient Selection in Sarcoma Care

Actual Study Start Date :

Oct 19, 2019

Anticipated Primary Completion Date :

Dec 31, 2029

Anticipated Study Completion Date :

Dec 31, 2029

Outcome Measures

Primary Outcome Measures

Diagnosis, [5 years]
Data collected in the registry will be evaluated and analyzed to determine criteria to improve treatment strategies
Local recurrence, [5 years]
s.o.
distant metastasis, [5 years]
s.o.
biopsy taken by operating surgeon-radiologist-team, [5 years]
s.o.
pathology centrally reviewed, [5 years]
s.o.
Surgery (yes/no), [5 years]
s.o.
Surgical margin status, [5 years]
s.o.
surgery performed by dedicated surgeon, [5 years]
s.o.
Radiation Therapy (yes/no), [5 years]
s.o.
Chemotherapy (yes/no), [5 years]
s.o.
decision of board carried out, [5 years]
s.o.
Status at last contact, [5 years]
s.o.

Eligibility Criteria

Criteria

Ages Eligible for Study:

N/A and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Malignant and intermediate and selected benign bone or soft tissue tumors, acc. to the WHO coding list of the SSN
Female and male subjects of all ages

Exclusion Criteria:

Documented objection of subsequent use of personal health data

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Kantonsspital Graubünden	Chur	Graubünden	Switzerland	7000
2	Ente Ospedaliero Cantonale	Bellinzona	Tessin	Switzerland	6500
3	Kantonsspital Winterthur	Winterthur	Zuerich	Switzerland	8400
4	SwissSarcomaNetwork	Winterthur	Zürich	Switzerland	8400
5	Luzerner Kantonsspital	Lucerne		Switzerland	6000
6	Pathologie Institut Enge	Zürich		Switzerland	8005
7	Klinik Hirslanden	Zürich		Switzerland	8032
8	Stadtspital Zürich Triemli	Zürich		Switzerland	8063

Sponsors and Collaborators

Kantonsspital Winterthur KSW
SwissSarcomaNetwork

Investigators

Principal Investigator: Bruno Fuchs, Prof, SwissSarcomaNetwork

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Kantonsspital Winterthur KSW

ClinicalTrials.gov Identifier:

NCT04300257

Other Study ID Numbers:

2019-01107

First Posted:

Mar 9, 2020

Last Update Posted:

Nov 30, 2021

Last Verified:

Nov 1, 2021

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Keywords provided by Kantonsspital Winterthur KSW

Sarcoma, Epithelioid

Sarcoma, Soft Tissue

Sarcoma, Spindle Cell

Sarcoma, Bone

Additional relevant MeSH terms:

Sarcoma

Study Results

No Results Posted as of Nov 30, 2021